COSM - Cosmos Health Inc.
After hours:
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.5500 |
| Open | 3.6000 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 1000 |
| Day's Range | 3.4698 - 3.6000 |
| 52 Week Range | 0.0680 - 23.8400 |
| Volume | |
| Avg. Volume | 445,719 |
| Market Cap | 39.771M |
| Beta (5Y Monthly) | 3.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -23.5500 |
| Earnings Date | May 16, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
ACCESSWIRECosmos Health set to join Russell Microcap Index
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions
- ACCESSWIRE
Cosmos Health Enters into Binding Letter of Intent for the Acquisition of Docpharm GmbH., an Established German Pharmaceutical Distributor; Expected to Boost Our Annual Revenue by Approximately €32M, or 70%, by the End of 2025 vs FY 2022.
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has executed a binding Letter of Intent (LOI) to acquire all of the outstanding shares of Docpharm GmbH.
- ACCESSWIRE
Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2023.
- ACCESSWIRE
Cosmos Health Enters Final Phase for the Acquisition of Cana Laboratories Following Conclusion of Stock Purchase Agreement
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has executed a Stock Purchase Agreement ("SPA") for, and has now entered the final phase for the acquisition of, Pharmaceutical Laboratories CANA S.A., ("Cana"), a Greek pharmaceutical company that manufactures,
- ACCESSWIRE
Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"), a fully licensed pharmaceutical wholesale company operating in the
- ACCESSWIRE
Cosmos Health Ends 2022 with Transformed Balance Sheet and Achieves Positive Adjusted EBITDA for the Fiscal Year 2022
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the fiscal year ended December 31, 2022.
- ACCESSWIRE
Cosmos Health Inc. to Participate in The Economist Annual New York-Eastern Mediterranean Business Summit on July 10th, 2023, with CEO Mr. Greg Siokas Delivering a Speech
Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it will participate in The Economist Annual New York-Eastern Mediterranean Business Summit entitled "A New Momentum for Geopolitics and Investment Cyprus-Greece-Israel." The event is scheduled to take place
- ACCESSWIRE
Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.
Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has successfully completed the acquisition of ZipDoctor, Inc. ("ZipDoctor") from American International Holdings Corp (AMIH).
- ACCESSWIRE
Cosmos Health Inc.'s UK Subsidiary Decahedron Ltd. Named Pharmaceutical Wholesaler of the Month in the Latest Issue of Healthcare Matters
Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that its subsidiary in the United Kingdom, Decahedron Ltd., has been named "Pharmaceutical Wholesaler of the Month" in the Mar/Apr 2023 issue of Healthcare Matters.
- ACCESSWIRE
Cosmos Health Inc. Enters into a Definitive Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.
Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a definitive agreement to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH) for an undisclosed sum.
- ACCESSWIRE
Cosmos Health Enters into a Material Definitive Agreement with Cana Laboratories
Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a material definitive agreement with Pharmaceutical Laboratories CANA S.A., ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded
- ACCESSWIRE
Cosmos Health Expects to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.
Cosmos Health Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has concluded its due diligence and is in the process of preparing the definitive documentation to complete the acquisition of ZipDoctor Inc. from American International Holdings Corp (AMIH).
- ACCESSWIRE
Cosmos Health Extends its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended its previously issued non-binding letter of intent (LOI) to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH).
- ACCESSWIRE
Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests
Cosmos Health Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the first purchase order to market and distribute Virax Biolabs' (Nasdaq: VRAX) ViraxClear branded COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.
PR NewswireVirax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus
- ACCESSWIRE
Cosmos Health Announces Application for Dual Listing on Upstream
Cosmos Health Inc. (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").
- ACCESSWIRE
Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer
Cosmos Health Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).
- ACCESSWIRE
Cosmos Health Retains Christian Levine Law Group to Further Monitor Trading Irregularities
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announces that in response to the data obtained through Shareholder Intelligence Services, it has retained services of Wes Christian of Christian Levine Law Group and Alan Pollack of Warshaw Burstein, LLP (the "Firms"), to help the company develop
- ACCESSWIRE
Cosmos Health Announces Stock Buyback Program
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock.
- ACCESSWIRE
Cosmos Health Extends and Updates its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended and updated its previously issued non-binding letter of intent to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH).
- ACCESSWIRE
Cosmos Health Provides an Update on its Debt Balance and Proforma Interest Expense
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced an update regarding its debt balance and proforma interest expense in 2023.
- ACCESSWIRE
Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended and updated its previously issued binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original
- ACCESSWIRE
Cosmos Health Regains Nasdaq Minimum Bid Price Compliance
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has successfully cured the Nasdaq minimum bid price deficiency.
- ACCESSWIRE
Cosmos Health CEO Participated in the Last Fundraising of the Company
Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that CEO Greg Siokas has participated with $3 million in the approximately $32.5 million financing of the Company completed yesterday, December 21, 2022, increasing to approximately $6 million his personal investments in the
- ACCESSWIRE
Cosmos Health Inc. Announces Successful Closing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
Cosmos Health Inc. (the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the closing of its previously announced registered direct offering of 2,828,320 shares of the Company's common stock and concurrent private placement of warrants to purchase 2,828,320 shares of the Company's common stock at a